Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Arm 1 | Patients receive oral brivanib alaninate daily in the absence of disease progression or unacceptable toxicity. Brivanib alaninate: Brivanib by mouth daily at a dose of 800mg. Polymerase chain reaction: Undergo 1241-cG250 PET/CT imaging (correlative studies) Iodine I 124 chimeric monoclonal antibody G250: Undergo 124I-cG250 PET/CT imaging (correlative studies) Positron emission tomography/computed tomography: Undergo 1241-cG250 PET/CT imaging (correlative studies) Protein expression analysis: Correlative studies Immunohistochemistry: correlative studies | 0 | None | 0 | 0 | 0 | 0 | View |